Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

類似資料

• Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
  著者:: Dörner, Thomas, 等
  出版事項: (2006)
• Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
  著者:: Steinfeld, Serge D, 等
  出版事項: (2006)
• Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
  著者:: Daridon, Capucine, 等
  出版事項: (2010)
• Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
  著者:: Gottenberg, Jacques‐Eric, 等
  出版事項: (2018)
• Treatment of systemic lupus erythematosus with epratuzumab
  著者:: Traczewski, Pawel, 等
  出版事項: (2011)